Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s traded shares stood at 3.85 million during the last session, with the company’s beta value hitting 0.72. At the close of trading, the stock’s price was $20.08, to imply an increase of 4.53% or $0.87 in intraday trading. The APLS share’s 52-week high remains $49.06, putting it -144.32% down since that peak but still an impressive 15.44% since price per share fell to its 52-week low of $16.98. The company has a valuation of $2.52B, with an average of 2.5 million shares in intraday trading volume over the past 10 days and average of 2.06 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Apellis Pharmaceuticals Inc (APLS), translating to a mean rating of 1.71. Of 14 analyst(s) looking at the stock, 0 analyst(s) give APLS a Sell rating. 1 of those analysts rate the stock as Overweight while 2 advise Hold as 11 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.34.
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
After registering a 4.53% upside in the last session, Apellis Pharmaceuticals Inc (APLS) has traded red over the past five days. The 5-day price performance for the stock is 14.48%, and -11.46% over 30 days. With these gigs, the year-to-date price performance is -37.07%. Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) saw shorts transact 26.83 million shares and set a 10.12 days time to cover.
The extremes give us $57 and $57 for target low and target high price respectively. As such, APLS has been trading -183.86% off suggested target high and -183.86% from its likely low.
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
The rating firms project that company’s revenue will grow 10.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 19 analysts is 195.9M. Meanwhile, for the current quarter, a total of 18 analyst(s) estimate revenue growth to 210.42M.Earnings reports from the last fiscal year show that sales brought in 172.32M and 199.69M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 13.68% before jumping 5.37% in the following quarter.
APLS Dividends
Apellis Pharmaceuticals Inc has its next earnings report out on 2025-Feb-27. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s Major holders
Apellis Pharmaceuticals Inc insiders hold 13.85% of total outstanding shares, with institutional holders owning 102.82% of the shares at 119.35% float percentage. In total, 102.82% institutions holds shares in the company, led by WELLINGTON MANAGEMENT GROUP LLP. As of 2024-06-30, the company held over 16.39 million shares (or 13.2269% of shares), all amounting to roughly $628.67 million.
The next major institution holding the largest number of shares is ECOR1 CAPITAL, LLC with 11.61 million shares, or about 9.3681% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $445.26 million.
We also have VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Apellis Pharmaceuticals Inc (APLS) shares. Going by data provided on Jan 31, 2025 , VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund holds roughly 8.48 shares. This is just over 6.75% of the total shares, with a market valuation of $170.23 million. Data from the same date shows that the other fund manager holds a little less at 3.26, or 2.60% of the shares, all valued at about 65.5 million.
